Our previous studies demonstrated that specific inhibition of the BIG3-PHB2 complex, which is a critical modulator in estrogen (E2) signaling, using ERAP, a dominant negative peptide inhibitor, leads to suppression of E2-dependent estrogen receptor (ER) alpha activation through the reactivation of the tumor suppressive activity of PHB2. Here, we report that ERAP has significant suppressive effects against synergistic activation caused by the crosstalk between E2 and growth factors associated with intrinsic or acquired resistance to anti-estrogen tamoxifen in breast cancer cells. Intrinsic PHB2 released from BIG3 by ERAP effectively disrupted each interaction of membrane-associated ERa and insulin-like growth factor 1 receptor beta (IGF-1Rb), EGFR, PI3K or human epidermal growth factor 2 (HER2) in the presence of E2 and the growth factors IGF or EGF, followed by inhibited the activation of IGF-1Rb, EGFR or HER2, and reduced Akt, MAPK and ERa phosphorylation levels, resulting in significant suppression of proliferation of ERa-positive breast cancer cells in vitro and in vivo. More importantly, combined treatment with ERAP and tamoxifen led to a synergistic suppression of signaling that was activated by crosstalk between E2 and growth factors or HER2 amplification. Taken together, our findings suggest that the specific inhibition of BIG3-PHB2 is a novel potential therapeutic approach for the treatment of tamoxifen-resistant breast cancers activated by the crosstalk between E2 and growth factor signaling, especially in premenopausal women.
Our previous studies demonstrated that specific inhibition of the BIG3-PHB2 complex, which is a critical modulator in estrogen (E2) signaling, using ERAP, a dominant negative peptide inhibitor, leads to suppression of E2-dependent estrogen receptor (ER) alpha activation through the reactivation of the tumor suppressive activity of PHB2. Here, we report that ERAP has significant suppressive effects against synergistic activation caused by the crosstalk between E2 and growth factors associated with intrinsic or acquired resistance to anti-estrogen tamoxifen in breast cancer cells. Intrinsic PHB2 released from BIG3 by ERAP effectively disrupted each interaction of membrane-associated ERa and insulin-like growth factor 1 receptor beta (IGF-1Rb), EGFR, PI3K or human epidermal growth factor 2 (HER2) in the presence of E2 and the growth factors IGF or EGF, followed by inhibited the activation of IGF-1Rb, EGFR or HER2, and reduced Akt, MAPK and ERa phosphorylation levels, resulting in significant suppression of proliferation of ERa-positive breast cancer cells in vitro and in vivo. More importantly, combined treatment with ERAP and tamoxifen led to a synergistic suppression of signaling that was activated by crosstalk between E2 and growth factors or HER2 amplification. Taken together, our findings suggest that the specific inhibition of BIG3-PHB2 is a novel potential therapeutic approach for the treatment of tamoxifen-resistant breast cancers activated by the crosstalk between E2 and growth factor signaling, especially in premenopausal women.
A ctivation of estrogen-receptor-a (ERa) by estrogen (E2) plays a pivotal role in the development and progression of breast cancer. (1) The biological actions of the E2-ERa complex are mediated by a genomic pathway acting directly as a transcription factor in the nucleus and a non-genomic pathway interacting with adjacent growth factor receptors, such as insulin-like growth factor 1 receptor (IGF-1R) and epidermal growth factor receptor (EGFR). (2) (3) (4) Accumulating evidence suggests a mechanistic crosstalk between the membrane-associated ERa and IGF-1R or EGFR signaling pathways whereby ERa forms a ternary complex of IGF-1R or EGFR, and Shc and activates its downstream signaling pathway, such as the MAPK and Akt cascade. (4) (5) (6) (7) (8) An interdependence between E2 and growth factor responses was confirmed in breast cancer cells in which the knockdown of ERa using small interfering RNA or inhibition by anti-estrogens prevented E2 and EGF stimulation of DNA synthesis. (9) Therefore, ERa is required for growth factor-mediated biological function, which suggests an important therapeutic target for breast cancer.
Current endocrine therapies for breast cancer are primarily based on targeting the ERa signaling pathways using antiestrogens, such as tamoxifen, or aromatase inhibitors that prevent E2 synthesis. (10, 11) However, up to 50% of patients with ERa-positive tumors either initially do not respond or become resistant to these drugs. (12, 13) Endocrine-resistance is a major clinical problem and leading cause of treatment failure and mortality. (14, 15) Mounting evidence suggests that the crosstalk between membrane-associated ERa and growth factor receptor pathways is one mechanism of the development of endocrine resistance. (16) Notably, increased ERa localization to the cytoplasm ⁄ membrane correlated with increased cytoplasmic signaling in endocrine-resistant MCF-7 cells. (17) Endocrine resistance in many tumors is associated with an overexpression or hyperactivation of proteins involved in ERa and IGF-1R ⁄ EGFR signaling. (18, 19) Therefore, one logical therapeutic approach in endocrine-resistant breast cancer is the combination of target therapies to block both ERa and growth factor signaling.
We previously reported that the oncoprotein brefeldin A inhibited the guanine nucleotide-exchange protein 3 (BIG3) and tumor suppressor prohibitin 2 (PHB2) complex, which plays a critical role in E2 signaling modulation in ERa-positive breast cancer, and resulted in constitutive ERa activation. (20, 21) We further demonstrated that a dominant-negative peptide, ERAP, specifically disrupted the BIG3-PHB2 interaction, and released the PHB2 tumor suppressive activity to inhibit both nuclear-associated and membrane-associated ERa activation. Intrinsic PHB2 binding to ERa completely inhibited ERa-IGF-1Rb and ⁄ or ERa-PI3K interactions and ERa phosphorylation at multiple sites in the presence of E2 in ERa-positive breast cancer cells, which may have suppressed acquired tamoxifen resistance in E2-dependent ERa-positive breast cancer cells. (21) However, the antitumor effects of ERAP on endocrine resistance that are associated with crosstalk between E2 and growth factor ligands and ERa and human epidermal growth factor 2 (HER2) signaling, which have been observed in primary breast cancers, are unclear.
Here, we report that ERAP has significant antitumor effects against the synergistic activation of crosstalk between E2 and several growth factor ligands and ⁄ or HER2 signaling in breast cancer cells.
Materials and Methods
Materials. A dominant-negative peptide (ERAP; 11R-GGG-QMLSDLTLQLRQR) designed to specifically inhibit BIG3-PHB2 interaction was synthesized as previously described. (21) Tamoxifen, IGF-1 and EGF were purchased from Sigma (St. Louis, MO, USA), Cell Signaling Technology (Danvers, MA, USA) and R&D Systems (Minneapolis, MN, USA), respectively. All chemicals were of analytical grade.
Cell lines and culture conditions. Human breast cancer cell lines (MCF-7 and BT-474) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The KPL-3C cells were kindly provided by Dr Jun-ichi Kurebayashi (Kawasaki Medical School, Kurashiki, Japan). (22) All of the cell lines were cultured according to previously described methods. (22) For the experiments using ERAP, the cells were incubated for 24 h and treated with 10 nM 17-estradiol (E2, Sigma) AE peptides (e.g. ERAP) as previously described. (22) Antibodies and immunoblot analyses. SDS-PAGE and immunoblot analyses were performed as described previously, (21) with antibodies against the following proteins: PHB2 (1:1000), ERa (phospho Y537; 1:500), ErbB2 ⁄ HER2 and phosphor-HER2 (pY877) (Abcam, Cambridge, UK); ERa (SP-1, 1:500; Thermo Fisher Scientific, Fremont, CA, USA); Akt, phosphoAkt (S473) (587F11, 1:1000), p44 ⁄ 42 MAPK, phospho-p44 ⁄ 42 MAPK (T202 ⁄ Y204) (1:1,000), Shc (1:500), phospho-Shc (Tyr239 ⁄ 240) (1H12, 1:500), phospho-ERa (S104 ⁄ S106; 1:500), IGF-1Rb (1:500), phospho-IGF-1Rb (Y1135 ⁄ 1136) (19H7, 1:500), EGFR (1:1000) and phospho-EGFR (Tyr1068) (1:500) (Cell Signaling Technology); PI3-kinase p85a (U13; 1:500) and phospho-ERa (S118; 1:500) (Santa Cruz Biotechnology, Santa Cruz, CA, USA); phospho-ERa (S167) (1:500) and phospho-ERa (S305) (1:500) (Merck Millipore, Billerica, MA, USA); phosphotyrosine (1:500) (Life Technologies, Rockville, MD, USA); and b-actin (AC-15; 1:5000) (Sigma). All of the experiments were performed in triplicate at minimum.
Immunoprecipitation. Immunoprecipitation was performed with 5 lg of antibodies against ERa, IGF-1Rb, EGFR and HER2 as described previously. (21) Subsequent SDS-PAGE and immunoblot analyses were performed as described above.
Luciferase reporter assay. Transfections of an ERE-luciferase reporter into MCF-7 cells were performed using an ERE reporter assay kit (Qiagen, Hilden, Germany) as previously described. (21) Briefly, the culture medium was changed to assay medium (Opti-MEM, 10% FBS, 0.1 mM NEAA, 1 mM sodium pyruvate and 10 lg ⁄ mL insulin) 16 h post-transfection. The cells were incubated for 8 h and exposed to E2 and ⁄ or IGF-1 or EGF in the presence of 10 lM ERAP for 24 h. Cells were harvested and analyzed for luciferase and Renilla-luciferase activities using the Promega dual luciferase reporter assay (Promega KK, Tokyo, Japan) as previously described. (21) Cell proliferation assay. Cell proliferation assays were performed using the Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) as previously described. (21) The data represent the mean AE SD of three independent experiments.
Cell cycle assay. The cell cycle assay was performed by flow cytometry using a FACSCalibur with CellQuest software (BD, Franklin Lakes, NJ, USA) as described previously. (21) In vivo tumor growth inhibition. We established an orthotropic xenograft tumor model in nude mice using the KPL-3C cells as previously described. (21) Tumors developed after a few days and reached sizes of approximately 100 mm 3 [calculated as 1 ⁄ 2 9 (width 9 length 2 )]. The mice were randomized into 13 treatment groups (five animals per group): (1) no treatment; (2) 6 lg E2 per day; (3) E2 + 14 mg ⁄ kg ⁄ day ERAP; (4) E2 + 4 mg⁄ kg ⁄ day tamoxifen; (5) E2 + ERAP + tamoxifen; (6) 10 lg ⁄ day IGF-1; (7) IGF-1 + ERAP; (8) IGF-1 + tamoxifen; (9) IGF-1 + ERAP + tamoxifen; (10) E2 + IGF-1; (11) E2 + IGF-1 + ERAP; (12) E2 + IGF-1 + tamoxifen; and (13) E2 + IGF-1 + ERAP + tamoxifen. E2 was delivered via the application of a solution to the neck skin. The other treatments were delivered via i.p. injection. Tumor volume was measured with calipers for 21 days, after which time the animals were killed, and the tumors were excised. All of the experiments were performed in accordance with the guidelines of the animal facility at the University of Tokushima.
Immunohistochemical staining of xenografts. We stained 3-lm sections of paraffin-embedded tumors with an anti-Ki-67 antibody (MIB-1, 1:50; Dako Japan, Tokyo, Japan) to examine Ki-67 expression in KPL-3C xenograft tumors.
TUNEL assay. Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assays were performed on paraffin sections from KPL-3C xenograft tumors using an in situ apoptosis detection kit (Takara, Shiga, Japan) as described previously. (23) Statistical analyses. Student's t-test was used to determine the significance of differences between the experimental groups. Values of P < 0.05 were considered significant.
Results
ERAP suppresses genomic and non-genomic estrogen receptor alpha signaling that is activated by crosstalk between E2 and insulin-like growth factor 1. We first investigated whether the dominant-negative peptide ERAP suppressed E2-dependent ERa transcriptional activity in the presence of the growth factor stimulator IGF-1 in breast cancer cells using a luciferase assay with an ERE reporter. The results showed that IGF-1 stimulation enhanced ERa transcriptional activity in the presence but not the absence of E2 in MCF-7 cells (Fig. 1a) , indicating that IGF-1 enhances E2-dependent ERa genomic action in cancer cells. Notably, ERAP treatment but not 10 nM tamoxifen significantly reduced the E2-dependent ERa transcriptional activity of MCF-7 cells after stimulation with IGF-1 (Fig. 1a) . Treatment with a combination of ERAP and tamoxifen significantly suppressed the crosstalk induced by E2 and IGF-1 compared with ERAP or tamoxifen alone (Fig. 1a) . These results suggest that treatment with a combination of ERAP and tamoxifen may additively suppress the ERa transcriptional activity stimulated by the crosstalk between E2 and IGF-1 in breast cancer cells.
We next investigated the effect of ERAP on the formation of ERa and IGF-1Rb or PI3K complexes in the presence of E2 and IGF-1 stimulation in MCF-7 cells. E2 and IGF-1 stimulation markedly enhanced IGF-1Rb tyrosine phosphory-lation and the interaction of ERa and IGF-1Rb, which was similar to E2 stimulation alone (Fig. 1b, IGF-1Rb: IP) . In contrast, stimulation of IGF-1 alone enhanced the tyrosine phosphorylation levels of both IGF-1Rb and PI3K but did not enhance ERa and IGF-1Rb or PI3K interactions. Notably, ERAP treatment stimulated the formation of a new complex consisting of IGF-1Rb, ERa and PHB2 released from BIG3, which suppressed IGF-1Rb and PI3K tyrosine phosphorylation levels (Fig. 1b, IGF-1Rb , ERa: IP) in the presence of E2 and IGF-1 in MCF-7 cells, respectively. An inhibitory effect of ERAP on IGF-1Rb tyrosine phosphorylation was observed in the presence of E2 and IGF-1 in KPL-3C cells, another ERapositive breast cancer cell line (Suppl. Fig. S1 ). ERAP treatment also interfered with the E2-induced and IGF-1-induced interaction of ERa and PI3K in MCF-7 cells (Fig. 1b , ERa: IP). We then examined the effects of ERAP on the phosphorylation status of Akt and MAPK, which are the downstream signaling molecules of IGF-1Rb and PI3K, respectively, in MCF-7 and BT474 cells, which strongly express IGF-1Rb (Suppl. Fig. S2 ). Crosstalk stimulation of E2 and IGF-1 clearly enhanced Akt (S473) and p42 ⁄ 44 MAPK (T202 ⁄ Y204) phosphorylation levels compared with E2 or IGF-1 alone, whereas treatment with ERAP but not tamoxifen completely suppressed both ligand-induced phosphorylation status in breast cancer cells (Fig. 1c,d) .
We also demonstrated that ERAP but not tamoxifen treatment abrogated ERa phosphorylation levels at five sites (S104 ⁄ S106, S118, S167, S305 and Y537) associated with ERa transcriptional activity, DNA-binding, co-activator binding, protein stability and cell proliferation in ERa-positive breast cancer cells after the combined stimulation of E2 and IGF-1 in MCF-7 and BT474 cells, respectively (Fig. 1e,f) . (24) (25) (26) (27) (28) (29) (30) (31) Notably, combination treatment with ERAP and tamoxifen completely suppressed ERa phosphorylation levels at all five sites in MCF-7 and BT474 cells (Fig. 1e,f) . Collectively, these results strongly suggest that ERAP interfered with E2-induced and IGF-1-induced signal pathways, and the combination ERAP and tamoxifen treatment caused an additive inhibitory effect of E2 and IGF-1-induced signaling pathways in breast cancer cells.
ERAP inhibits the estrogen receptor alpha-positive breast cancer cell growth activated by the crosstalk between E2 and insulin-like growth factor 1. We next elucidated the inhibitory effect of ERAP on E2-dependent cell proliferation in the presence of IGF-1 stimulation in MCF-7 and BT474 cells using the MTT assay. IGF-1 stimulation significantly enhanced proliferation in the presence of E2 and in the absence of E2 in both cancer cell lines (Fig. 2a,b) . Figure 1a shows that treatment with IGF-1 alone did not enhance ERa transcriptional activity in MCF-7 cells. These findings suggest that IGF-1 stimulation enhances an E2-independent proliferation of ERa-positive breast cancer cells. Notably, ERAP treatment but not 10 nM tamoxifen treatment significantly reduced the growth of MCF-7 cells after E2 and IGF-1 stimulation (Fig. 2a,b) . In contrast, ERAP treatment had no effect on IGF-1-induced cell growth in the absence of E2 (Fig. 2a,b) , indicating that ERAP suppressed E2-dependent IGF-1 signaling in breast cancer cells. Furthermore, treatment with a combination of ERAP and tamoxifen synergistically suppressed the cell growth activated by the crosstalk between E2 and IGF-1 compared with ERAP or tamoxifen alone (Fig. 2a,b) . These results suggest that ERAP suppressed endocrine-resistant breast cancer, which is associated with the crosstalk between the E2 and IGF-1 signaling pathways.
We examined the effects of ERAP on cell cycle distribution in response to E2 and IGF-1 crosstalk using flow cytometry. The population of cells in the G2 ⁄ M phase markedly increased after a 24 h crosstalk stimulation, whereas the population in the G1 phase increased after ERAP or tamoxifen treatment. These results indicate growth suppression via the induction of G1 arrest (ERAP; 57.0%, tamoxifen; 36.6%) (Fig. 2c) . Notably, a remarkable increase in the sub-G1 cell population (apoptotic cell) was observed after treatment with a combination of ERAP and tamoxifen (24.9%) (Fig. 2c) . These findings strongly suggest that ERAP treatment suppressed cell growth of endocrine-resistant breast cancer cells due to crosstalk between E2 and IGF-1, which induced a G1 arrest, and the combination treatment of ERAP and tamoxifen synergistically suppressed cell growth by inducing rapid apoptosis.
ERAP inhibits the breast tumor growth activated by the crosstalk between E2 and insulin-like growth factor 1 in vivo. KPL-3C orthotropic breast cancer xenografts were developed in nude mice to determine the anti-tumor activity of ERAP against E2 and IGF-1 crosstalk in vivo. Once the tumors were fully established, ERAP (14 mg ⁄ kg ⁄ day), tamoxifen (4 mg ⁄ kg ⁄ day), a combination of ERAP and tamoxifen, or vehicle alone were administered daily via i.p. injection for 21 days. The animals also received daily treatments of E2 (6 lg ⁄ day), IGF-1 (10 ng ⁄ day), or a combination of E2 and IGF- (Fig. 3a, Suppl. Fig. S3a-c) . In contrast, ERAP treatment but not tamoxifen treatment significantly inhibited the tumor growth induced by the co-stimulation of E2 and IGF-1 (Fig. 3a, Suppl. Fig. S3c ; n = 5; P < 0.01 in two-sided Student's t-test). Unexpectedly, ERAP significantly inhibited IGF-1 alone-induced tumor growth in vivo, in contrast to in vitro, suggesting that the suppression of IGF-1-induced signaling pathways is associated with in vivo tumor formation by ERAP (Fig. 3a, middle) . No toxicity or significant body weight losses were observed with any treatments throughout these experiments (Fig. 3b) .
We next examined the in vivo inhibitory effects of ERAP on the activation of the non-genomic ERa-signaling pathway using co-stimulation with E2 and IGF-1. As expected, ERAP treatment considerably suppressed both Akt and MAPK phosphorylation levels in tumors, and this suppression was comparable to combined treatment with ERAP and tamoxifen (Fig. 3c) , which is consistent with the in vitro inhibitory effect (Fig. 1c,d) . We further investigated the expression of the proliferative markers Ki-67 using immunohistochemistry. The results showed that the number of cells expressing Ki-67 was extremely increased in tumors treated with E2 and IGF-1 (Fig. 3d, upper panels) and drastically decreased after the combined treatment of ERAP and tamoxifen (Fig. 3d, upper panels) . Furthermore, a significant induction of TUNEL-positive apoptotic tumor cells were observed after the combined treatment of ERAP and tamoxifen ( Fig. 3d ; lower panels), but only a slight induction of TUNEL-positive apoptotic tumors were observed after ERAP or tamoxifen alone ( Fig. 3d ; lower panels). Consistent with this result, treatment with ERAP or tamoxifen alone showed lower Ki-67 expression than the crosstalk between E2 and IGF-1. These results suggest a slight induction of apoptosis in addition to G1 arrest by treatment with ERAP or tamoxifen alone.
ERAP regulates the signaling crosstalk of E2 and epidermal growth factor or human epidermal growth factor 2. Endogenous membrane-associated ERa has been shown to exhibit crosstalk to the trans activation of EGF and HER2 in breast cancer cells. (32, 33) We first measured the proliferation of BT-474 cells overexpressing EGFR and HER2 using the MTT assay at 24 h after ERAP treatment to examine the inhibitory effects of ERAP on the activation of signal pathways stimulated by the crosstalk of E2 and EGF. The results showed that ERAP treatment but not tamoxifen treatment significantly inhibited cell growth that was enhanced by the crosstalk of both E2 and EGF in BT-474 cells (Fig. 4a) . Notably, the combined treatment of ERAP and tamoxifen significantly suppressed each crosstalk-induced cell proliferation. This combination showed a synergistic inhibitory effect on EGF-induced cell growth (Fig. 4a) , which was unlike the effect in MCF-7 cells (Fig. 2a) . These results suggest the possibility that this difference was due to different expression levels of EGFR between BT-474 and MCF-7 cells (Suppl. Fig. S2 ). Furthermore, ERAP treatment remarkably suppressed Akt (S473) and p42 ⁄ 44 MAPK (T202 ⁄ Y204) and ERa phosphorylation levels at five sites (S104 ⁄ S106, S118, S167, S305 and Y537) activated by the crosstalk between E2 and EGF, which was comparable to the combined treatment of ERAP and tamoxifen (Fig. 4b) .
Amplification of the HER2 oncogene occurs in approximately 15% of invasive breast cancers and the mechanism of tamoxifen resistance for which clinical data exist, is the overexpression of HER2. (34) (35) (36) (37) (38) We performed experiments to clarify the inhibitory effects of the interactions of ERa with HER2, EGFR or IGF-1Rb in BT-474 cells to further elucidate the potential role of ERAP against the crosstalk responsible for endocrine resistance. Co-immunoprecipitation experiments revealed that ERAP completely inhibited all of the complex formation of endogenous ERa with EGFR (Fig. 4c,d ), HER2 (Fig. 4c,e) , IGF-1Rb (Fig. 4c) or PI3K (Fig. 4c) in the presence of E2 in BT474 cells. Recently, we demonstrated that ERAP removed Shc from a ternary complex of ERa, IGF-1Rb and Shc in the cell membrane of MCF-7 and KPL-3C cells and formed a new ternary complex consisting of ERa, IGF1Rb and PHB2. (21) We also demonstrated that ERAP removed Shc from a ternary complex of ERa, Shc and EGFR or HER2 in the cell membrane and formed a new complex consisting of EGFR, ERa and PHB2 or HER2, ERa and PHB2 (Fig. 4d,e) . These new complexes suppressed E2-induced tyrosine phosphorylation of EGFR or HER2 by ERAP treatment (Fig. 4d,e) . Therefore, our data suggest that PHB2, which is released from BIG3 by ERAP, removed Shc and inhibited the E2-dependent interactions of ERa and EGFR, HER2 and IGF-1Rb. This inhibition may have suppressed the signaling pathways associated with endocrine-resistant breast cancers (Fig. 4f) .
Discussion
This study demonstrated that ERAP had significant inhibitory effects against signaling crosstalk between E2 and growth factors, such as IGF and EGF, and HER2 amplification through its complete inhibition of ERa-IGF-1Rb, ERa-EGFR, ERa-HER2 and ⁄ or ERa-PI3K interactions. This mechanism of the inhibitory effect of ERAP was possibly due to the removal of the Shc adaptor protein from each complex and the formation of new complexes that included PHB2 released from BIG3. ERAP considerably suppressed the activation of signaling pathways, including Akt and MAPK, which are activated by the crosstalk between E2 and IGF or EGF and associated with tamoxifen resistance. We also demonstrated that ERAP suppressed E2-dependent ERa transcriptional activity in the presence of IGF-1 in breast cancer cells (Fig. 1a) . Moreover, we previously reported that PHB2 released from BIG3 by ERAP treatment directly binds to ERa and acts as a corepressor by recruiting HDAC1 and NcoR, thereby leading to an almost complete suppression of the ERa target gene expression. (21) Accordingly, these findings suggest the possibility that ERAP also represses ERa transcriptional activity stimulated by cros- stalk with E2 and IGF-1 in breast cancer cells via the same mechanism. More interestingly, accumulating evidence indicates that PHB2 also represses other transcriptional regulators such as MyoD, MEF2, EZH2 and RNF2-dependent transcriptional activities. (39) This evidence suggests the possibility that ERAP may represses several transcriptional activities, including ERa by PHB2, although further analyses are needed to elucidate the detailed mechanisms of the inhibitory effects.
ERAP also remarkably reduced the phosphorylation levels at all five sites within ERa (S104 ⁄ S106, S118, S167, S305 and Y537) activated by E2 and IGF-1 or EGF stimulation. Considerable data indicate that ERa is activated by a variety of kinase growth factor signaling pathways, including ERK1 ⁄ 2, p38MAPK, p21-activated kinase (PAK-1), Akt, c-Src and protein kinase A (PKA). For example, phosphorylation of ERa S118 by Erk1 ⁄ 2 and S167 by Akt are involved in acquired tamoxifen resistance. (40) (41) (42) Both PAK-1-and PKA-mediated phosphorylation of S305 are associated with tamoxifen responsiveness. (43, 44) Our findings suggest that ERAP downregulated ERa phosphorylation levels due to a direct or indirect suppression of these kinase activities, and further elucidation of the mechanisms of the inhibitory effects of ERa phosphorylation is required.
The biological actions of E2 have been shown to require the activation of E2-responsive genes and cell membrane-initiated events operated via Src, adaptor protein Shc, and growth factor receptors, such as IGF-1R, EGFR and HER2. (45, 46) Membraneassociated ERa transduces E2 rapid signals, which lead to the synergistic activation of IGF-1R and EGFR in breast cancer. (47) Interestingly, long-term blockade of ERa function with tamoxifen irreversibly causes the overexpression of EGRF or HER2, which results in functional EGFR pathways instead of ERa-signaling. (48) Clinical evidence has shown that ERa, IGF-1R and EGFR are co-expressed in breast cancer at the time tumors are diagnosed. (49, 50) The overexpression of HER2 and EGFR is associated with poorer outcome in breast cancer patients treated with endocrine therapy. (34) (35) (36) Based on the above findings, clinical trials were conducted and demonstrated that the combination of gefitinib (Iressa), a potent EGFR inhibitor, with an anti-estrogen agent was more efficient at inhibiting ERa-positive breast cancer growth than either agent alone. (51) More importantly, we revealed that the combination of ERAP and tamoxifen induced rapid apoptosis in vivo and in vitro against breast cancer cells exposed to the crosstalk of E2 and growth factors compared with either treatment alone. This combined effect suggests that the release of intrinsic PHB2 could modulate multiple aspects of the synergistic signaling network through E2 and growth factors, in addition to the transcriptional repressor for ERa. Therefore, a combination of the current endocrine therapies and BIG3-PHB2 interaction inhibitors may lead to more effective combined effects on intrinsic and acquired endocrine-resistant breast cancer, especially in premenopausal women. These molecular findings provide the rationale for clinical studies of endocrine therapy to block growth factor signaling pathways and restore endocrine responsiveness.
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